Disease-Targeted Treatment Translation in Fragile X Syndrome as a Model for Neurodevelopmental Disorders
- PMID: 35791522
- DOI: 10.1177/08830738221089740
Disease-Targeted Treatment Translation in Fragile X Syndrome as a Model for Neurodevelopmental Disorders
Abstract
Fragile X syndrome (FXS), the most common monogenic cause of intellectual disability and autism spectrum disorder, has been one of the first neurodevelopmental disorders in which molecular and neuronal mechanisms of disease were identified, leading to the concept of targeting the underlying disease to reverse symptoms. Translating findings in basic science and animal models to humans with FXS has proven difficult. These challenges have prompted the FXS field to organize to build interlocking projects and initiatives to improve consistency of supportive care, make clinical research accessible to families, generate collaborative research on natural history, outcome measures and biomarkers, and create clinical trial consortia and novel trial designs. This work has resulted in improved success in recent clinical trials, providing key steps toward regulatory approval of disease-targeted treatments for FXS. Progress in the FXS field has informed translation of transformative new disease-targeted therapies for other monogenic neurodevelopmental disorders.
Keywords: fragile X syndrome; neurodevelopmental disorder; outcome measures; targeted treatment.
Similar articles
-
Fragile X Syndrome: Supportive Treatment, Unmet Needs, and Paths to Novel Interventions and Disease-Targeted Therapies.Am J Intellect Dev Disabil. 2022 Mar 1;127(2):90-94. doi: 10.1352/1944-7558-127.2.90. Am J Intellect Dev Disabil. 2022. PMID: 35180774
-
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back.Neurotherapeutics. 2015 Jul;12(3):584-608. doi: 10.1007/s13311-015-0355-9. Neurotherapeutics. 2015. PMID: 25986746 Free PMC article. Review.
-
Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.Int J Mol Sci. 2017 Jun 20;18(6):1314. doi: 10.3390/ijms18061314. Int J Mol Sci. 2017. PMID: 28632163 Free PMC article. Review.
-
[Clinical practice guidelines for Fragile X syndrome].Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2022 Nov 10;39(11):1181-1186. doi: 10.3760/cma.j.cn511374-20220819-00564. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2022. PMID: 36317200 Chinese.
-
State-of-the-art therapies for fragile X syndrome.Dev Med Child Neurol. 2024 Jul;66(7):863-871. doi: 10.1111/dmcn.15885. Epub 2024 Feb 22. Dev Med Child Neurol. 2024. PMID: 38385885 Review.
Cited by
-
Challenges in developing therapies in fragile X syndrome: how the FXLEARN trial can guide research.J Clin Invest. 2024 Mar 1;134(5):e175036. doi: 10.1172/JCI175036. J Clin Invest. 2024. PMID: 38426491 Free PMC article.
-
Effects of AFQ056 on language learning in fragile X syndrome.J Clin Invest. 2023 Aug 31;134(5):e171723. doi: 10.1172/JCI171723. J Clin Invest. 2023. PMID: 37651202 Free PMC article. Clinical Trial.
-
Age-Dependent Dysregulation of APP in Neuronal and Skin Cells from Fragile X Individuals.Cells. 2023 Feb 27;12(5):758. doi: 10.3390/cells12050758. Cells. 2023. PMID: 36899894 Free PMC article.
-
Fragile X Syndrome: Recent Research Updates toward Capturing Treatments' Improvement in Clinical Trials.Brain Sci. 2022 Sep 22;12(10):1276. doi: 10.3390/brainsci12101276. Brain Sci. 2022. PMID: 36291209 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
